Merck Sharp & Dohme Ltd v Ono Pharmaceutical Co. Ltd and another; Bristol Myers Squibb Company and others v Merck & Co Inc and another [2015] EWHC 2973 (Pat), [2015] All ER (D) 07 (Nov)
The Patents Court considered a patent relating to the use of anti-PD-1 antibodies in the treatment of cancer. The court rejected a number of objections to the validity of the patent, including lack of novelty, obviousness and entitlement to the first priority date.
